TGF-β信号通路在骨髓增生异常综合征中作用机制的研究进展

doi:10.11958/20231620

天津医药 ›› 2024, Vol. 52 ›› Issue (7): 781-784.doi: 10.11958/20231620

• 综述 • 上一篇

TGF-β信号通路在骨髓增生异常综合征中作用机制的研究进展

刘青青¹(), 李宜蔷¹, 石玉士¹, 陆海颂², 程纬民²^,^∆()

1 广西中医药大学研究生学院（邮编530001）
2 广西中医药大学第一附属医院血液内科

收稿日期:2023-11-09 修回日期:2024-01-11 出版日期:2024-07-15 发布日期:2024-07-11
通讯作者: ^∆E-mail：cheng5min@126.com
作者简介:刘青青（1996），女，硕士在读，主要从事血液系统疾病相关机制方面研究。E-mail：571230817@qq.com
基金资助:
广西中医药管理局资助项目(GZZC2019058)

Research progress on the mechanism of the TGF-β signaling pathway in myelodysplastic syndrome

LIU Qingqing¹(), LI Yiqiang¹, SHI Yushi¹, LU Haisong², CHENG Weimin²^,^∆()

1 Graduate School of Guangxi University of Traditional Chinese Medicine, Nanning 530001, China
2 Department of Hematology, First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine

Received:2023-11-09 Revised:2024-01-11 Published:2024-07-15 Online:2024-07-11
Contact: ^∆E-mail：cheng5min@126.com

刘青青, 李宜蔷, 石玉士, 陆海颂, 程纬民. TGF-β信号通路在骨髓增生异常综合征中作用机制的研究进展[J]. 天津医药, 2024, 52(7): 781-784.

LIU Qingqing, LI Yiqiang, SHI Yushi, LU Haisong, CHENG Weimin. Research progress on the mechanism of the TGF-β signaling pathway in myelodysplastic syndrome[J]. Tianjin Medical Journal, 2024, 52(7): 781-784.

摘要/Abstract

摘要：

骨髓增生异常综合征（MDS）是一种细胞遗传学与分子遗传学高度异质性的恶性克隆性疾病，且进展为急性髓系白血病（AML）的风险极高。转化生长因子-β（TGF-β）与MDS的发病密切相关，是免疫稳态及免疫耐受的关键执行者，可抑制免疫系统许多组成部分的扩张和功能。TGF-β信号通路能调控微环境中的造血细胞及免疫细胞，抑制其发挥正常生物学功能，从而加快MDS的疾病进展。就近年来TGF-β信号通路对MDS红细胞、T淋巴细胞、自然杀伤细细胞、巨噬细胞的调控作用进行综述，以期为MDS的发病机制及治疗提供新的视角。

关键词: 骨髓增生异常综合征, 转化生长因子β, 信号传导, 免疫细胞, 作用机制

Abstract:

Myelodysplastic syndrome (MDS) is a malignant clonal disease with high heterogeneity in cytogenetics and molecular genetics, and the risk of progression to acute myeloid leukemia (AML) is extremely high. Transforming growth factor-β (TGF-β) is closely related to the pathogenesis of MDS. It is a key executor of immune homeostasis and immune tolerance, and can inhibit the expansion and function of many components of immune system. TGF-β signaling pathway can regulate hematopoietic cells and immune cells in microenvironment, inhibit their normal biological functions, and thus accelerate the progression of MDS. This study reviews regulatory effects of TGF-β signaling pathway on MDS blood cells, T lymphocytes, natural killer cells and macrophages in recent years, and provides a new perspective for the pathogenesis and treatment of MDS.

Key words: myelodysplastic syndromes, transforming growth factor beta, signal transduction, immune cells, mechanism of action

中图分类号:

R552

参考文献 37

[1]	BUCKSTEIN R, CHODIRKER L, YEEK W L, et al. The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts:an analysis of the prospective MDS-CAN registry[J]. Leuk Lymphoma, 2023, 64(3):651-661. doi:10.1080/10428194.2022.2156793.
[2]	VEGIVINTI C T R, KEESARI P R, VEERABALLI S, et al. Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML:a narrative review[J]. Exp Hematol Oncol, 2023, 12(1):1-12. doi:10.1186/s40164-023-00422-1.
[3]	PELLAGATTI A, BOULTWOOD J. Splicing factor mutations in the myelodysplastic syndromes:role of key aberrantly spliced genes in disease pathophysiology and treatment[J]. Adv Biol Regul, 2023,87:100920. doi:10.1016/j.jbior.2022.100920.
[4]	FENG Y, LIANG H, LUO X, et al. Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome[J]. Hematology, 2023, 28(1):2220222. doi:10.1080/16078454.2023.2220222.
[5]	FATTIZZO B, VERSINO F, BORTOLOTTI M, et al. Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts:stimulating early and late-stage erythropoiesis[J]. Eur J Haematol, 2023, 110(5):571-574. doi:10.1111/ejh.13933.
[6]	TIE Y, TANG F, PENG D, et al. TGF-beta signal transduction:biology,function and therapy for diseases[J]. Mol Biomed, 2022, 3(1):45. doi:10.1186/s43556-022-00109-9.
[7]	DELANGHE S, NGUYEN T Q, MAZURE D, et al. Immune complex glomerulonephritis in a patient with myelodysplastic syndrome with ring sideroblasts treated with luspatercept[J]. Diagnostics, 2022, 13(1):11. doi:10.3390/diagnostics13010011.
[8]	MUENCH D E, FERCHEN K, VELU C S, et al. SKI controls MDS-associated chronic TGF-β signaling,aberrant splicing,and stem cell fitness[J]. Blood, 2018, 132(21):e24-e34. doi:10.1182/blood-2018-06-860890.
[9]	韩冰, 李红敏, 陈芳菲, 等. 骨髓增生异常综合征贫血原因及治疗策略[J]. 天津医药, 2018, 46(8):794-798.
	HAN B, LI H M, CHENG F F, et al. Etiology and treatment strategies of anemia in myelodysplastic syndromes[J]. Tianjin Med J, 2018, 46(8):794-798. doi:10.11958/20180561.
[10]	CANAANI J. Emerging therapies for the myelodysplastic syndromes.[J]. Clinical hematology international, 2020, 2(1):13-17. doi:10.2991/chi.d.191202.001.
[11]	LECOMTE S, DEVREUX J, de STREEL G, et al. Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis[J]. Blood, 2023, 141(5):490-502. doi:10.1182/blood.2022017097.
[12]	ZHANG Y, YE T, GONG S, et al. RNA-sequencing based bone marrow cell transcriptome analysis reveals the potential mechanisms of E'jiao against blood-deficiency in mice[J]. Biomed Pharmacother, 2019,118:109291. doi: 10.1016/j.biopha.2019.109291.
[13]	SURAGANI R N V S, CADENA S M, CAWLEY S M, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis[J]. Nature medicine, 2014, 20(4):408-414. doi:10.1038/nm.3512.
[14]	BRUZZESE A, VIGNA E, MARTINO E A, et al. Myelodysplastic syndromes with ring sideroblasts[J]. Hematol Oncol, 2023, 41(4):612-620. doi:10.1002/hon.3125.
[15]	KOUROUKLI O, SYMEONIDIS A, FOUKAS P, et al. Bone marrow immune microenvironment in myelodysplastic syndromes[J]. Cancers, 2022, 14(22):5656. doi:10.3390/cancers14225656.
[16]	NAKAJIMA H. Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes[J]. Rinsho Ketsueki, 2023, 64(8):753-763. doi:10.11406/rinketsu.64.753.
[17]	SUWABE T, SHIBASAKI Y, SATO H, et al. WT1-specific CD8+ cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS[J]. Int J Hematol, 2021,113:723-734. doi:10.1007/s12185-021-03083-0.
[18]	ZHANG X, YANG X, MA L, et al. Immune dysregulation and potential targeted therapy in myelodysplastic syndrome[J]. Ther Adv Hematol, 2023,14:20406207231183330. doi:10.1177/20406207231183330.
[19]	YI M, NIU M, XU L, et al. Regulation of PD-L1 expression in the tumor microenvironment[J]. J Hematol Oncol, 2021, 14(1):10.
[20]	CHOKR N, PATEL R, WATTAMWAR K, et al. The rising era of immune checkpoint inhibitors in myelodysplastic syndromes[J]. Adv Hematol, 2018,2018:2458679. doi:10.1155/2018/2458679.
[21]	VAN DORP J, VAN DER HEIJDEN M S. The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition[J]. Front Immunol, 2023,14:1235884. doi:10.3389/fimmu.2023.1235884.
[22]	GULLEY J L, SCHLOM J, BARCELLOS-HOFF M H, et al. Dual inhibition of TGF-β and PD-L1:a novel approach to cancer treatment[J]. Molecular oncology, 2022, 16(11):2117-2134. doi:10.1002/1878-0261.13146
[23]	YI M, LI T, NIU M, et al. TGF-β:a novel predictor and target for anti-PD-1/PD-L1 therapy[J]. Front Immunol, 2022,13:1061394. doi:10.3389/fimmu.2022.1061394.
[24]	DE STREEL G, BERTRAND C, CHALON N, et al. Selective inhibition of TGF-β1 produced by GARP-expressing tregs overcomes resistance to PD-1/PD-L1 blockade in cancer[J]. Nat Commun, 2020, 11(1):4545. doi:10.1038/s41467-020-17811-3.
[25]	CHIEN K S, KIM K, NOGUERAS-GONZALEZ G M, et al. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome[J]. Br J Haematol, 2021, 195(3):378-387. doi:10.1111/bjh.17689.
[26]	ARELLANO-BALLESTERO H, SABRY M, LOWDELL M W. A killer disarmed:natural killer cell impairment in myelodysplastic syndrome[J]. Cells, 2023, 12(4):633. doi:10.3390/cells12040633.
[27]	SHAIM H, SHANLEY M, BASAR R, et al. Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells[J]. J Clin Invest, 2021, 131(14):e142116. doi:10.1172/JCI142116.
[28]	HUANGC H, LIAO Y J, CHIOU T J, et al. TGF-β regulated leukemia cell susceptibility against NK targeting through the down-regulation of the CD48 expression[J]. Immunobiology, 2019, 224(5):649-658. doi:10.1016/j.imbio.2019.07.002.
[29]	REGIS S, DONDERO A, CALIENDO F, et al. NK cell function regulation by TGF-β-induced epigenetic mechanisms[J]. Front Immunol, 2020,11:311. doi:10.3389/fimmu.2020.00311.
[30]	CASU B, DONDERO A, REGIS S, et al. Novel immunoregulatory functions of IL-18,an accomplice of TGF-β1[J]. Cancers, 2019, 11(1):75. doi:10.3390/cancers11010075.
[31]	LEE Y S, CHOI H, CHO H R, et al. Downregulation of NKG2DLs by TGF-β in human lung cancer cells[J]. BMC Immunol, 2021, 22(1):44. doi:10.1186/s12865-021-00434-8.
[32]	BURGA R A, YVON E, CHORVINSKY E, et al. Engineering the TGF-β receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastoma[J]. Clin Cancer Res, 2019, 25(14):4400-4412. doi:10.1158/1078-0432.CCR-18-3183.
[33]	PITTET M J, MICHIELIN O, MIGLIORINI D. Clinical relevance of tumour-associated macrophages[J]. Nat Rev Clin Oncol, 2022, 19(6):402-421. doi:10.1038/s41571-022-00620-6.
[34]	ELADL E, TREMBLAY-LEMAY R, RASTGOO N, et al. Role of CD47 in hematological malignancies[J]. J Hematol Oncol, 2020, 13(1):96. doi:10.1186/s13045-020-00930-1.
[35]	CHAO M P, TAKIMOTO C H, FENG D D, et al. Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies[J]. Front Oncol, 2020,9:1380. doi:10.3389/fonc.2019.01380.
[36]	LI W, WANG F, GUO R, et al. Targeting macrophages in hematological malignancies:recent advances and future directions[J]. J Hematol Oncol, 2022, 15(1):110. doi:10.1186/s13045-022-01328-x.
[37]	TAJBAKHSH A, MOVAHEDPOUR A, SAVARDASHTAKI A, et al. The complex roles of efferocytosis in cancer development,metastasis,and treatment[J]. Biomed Pharmacother, 2021,140:111776.

TGF-β信号通路在骨髓增生异常综合征中作用机制的研究进展

Research progress on the mechanism of the TGF-β signaling pathway in myelodysplastic syndrome

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 37

相关文章 15

编辑推荐

Metrics

本文评价

[1]	丁培森, 刘思雨, 邢志磊, 于晓猛, 宋佳慧, 崔玉山, 刘洪亮. 基于VOSviewer的甲状腺癌分子与细胞生物学领域的可视化分析[J]. 天津医药, 2024, 52(9): 985-990.
[2]	孙延文, 王聪, 陈世良, 张冉冉. 骨髓增生异常综合征相关的血脂异常分析[J]. 天津医药, 2024, 52(8): 872-876.
[3]	胡娜, 李正宇, 叶春风, 吴英, 姚庆, 黄世祥, 李文, 朱海琴. miR-10b靶向TGFBR1/SMAD3通路对特发性矮小症的软骨细胞增殖、肥大的影响机制[J]. 天津医药, 2024, 52(2): 124-128.
[4]	张琳琳, 赵唐明, 黄婵, 李善文, 甘卫华. 新型多肽AMPP2在TGF-β1诱导的系膜细胞增殖中的作用及其机制[J]. 天津医药, 2024, 52(1): 50-55.
[5]	张立群, 乌日吉木斯, 郑晓明, 汪琳, 韩玉秀, 张薇, 阎涛. circFAT1对胶质母细胞瘤细胞生物过程的机制研究[J]. 天津医药, 2023, 51(8): 797-802.
[6]	苏博洋, 何正卿, 黄旭升. 肌萎缩侧索硬化相关免疫细胞的研究进展[J]. 天津医药, 2023, 51(7): 697-700.
[7]	陈立喜, 陈元良, 卓泽铭, 王和杰. 利奈唑胺对MRSA感染致慢性骨髓炎大鼠细菌负荷和骨修复的影响[J]. 天津医药, 2023, 51(7): 729-733.
[8]	葛塬, 马佐鹏, 王延华. 金丝桃苷抑制鼻咽癌细胞生物学行为的分子机制研究[J]. 天津医药, 2023, 51(4): 344-350.
[9]	郑君毅, 李晓凤, 郭绪昆. 褪黑素对心肌缺血再灌注损伤的保护作用及机制[J]. 天津医药, 2023, 51(10): 1054-1058.
[10]	黄彬, 张军, 郑金旭△, 丁慢玲, 吴妍. circ_0007762通过miR-18a-5p调节肺成纤维细胞自噬的机制研究[J]. 天津医药, 2022, 50(6): 571-578.
[11]	王琼, 詹江华△. 瘦素对肝星状细胞活化的调控及其在肝纤维化进展中的作用[J]. 天津医药, 2022, 50(1): 25-29.
[12]	栾宁 , 刘丹 , 刘畅 , 王新杨 , 侯阳 , 张晓妍 . LTBP2通过TLR4/NF-κB信号通路抑制糖尿病大鼠海马神经元凋亡[J]. 天津医药, 2021, 49(8): 812-817.
[13]	王威威, 尹相云, 邵一鸣, 孙建生, 连鸿凯. 膝骨关节炎患者血清血小板反应蛋白-1水平变化及临床意义#br#[J]. 天津医药, 2021, 49(4): 419-423.
[14]	徐子寒, 彭云, 董世强, 侯定坤, 王海涛. Survivin异常表达对前列腺癌转移及TGF-β/Smad通路的调节作用#br#[J]. 天津医药, 2021, 49(4): 342-348.
[15]	李丽华, 王玉娇, 李俊雄, 李思玉, 唐婉容, 邱亚. 白藜芦醇抑制人牙龈成纤维细胞炎症和氧化应激的机制研究[J]. 天津医药, 2021, 49(12): 1245-1249.